|
24 Jan 2020 |
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
|
|
23 Jan 2020 |
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
|
|
23 Jan 2020 |
Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)
|
|
23 Jan 2020 |
BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders
|
|
23 Jan 2020 |
Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
|
|
23 Jan 2020 |
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy
|
|
22 Jan 2020 |
Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Health Markers
|
|
22 Jan 2020 |
INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA
|
|
22 Jan 2020 |
Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients
|
|
22 Jan 2020 |
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
|
|
22 Jan 2020 |
LB Pharmaceuticals Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia
|
|
22 Jan 2020 |
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
|
|
21 Jan 2020 |
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
|
|
21 Jan 2020 |
Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8
|
|
21 Jan 2020 |
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
|
|
21 Jan 2020 |
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
|
|
21 Jan 2020 |
Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis
|
|
21 Jan 2020 |
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
|
|
21 Jan 2020 |
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
|
|
21 Jan 2020 |
HepaRegeniX GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic
|
|
20 Jan 2020 |
Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early
|
|
20 Jan 2020 |
Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC
|
|
20 Jan 2020 |
Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
|
20 Jan 2020 |
Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer
|
|
17 Jan 2020 |
Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Disease
|
